Vista Pharmaceuticals Limited

VISTAPH6

INE427C01021

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 04:55:57 2024-05-29 am EDT			5-day change	1st Jan Change
13.39 ^INR	+3.72%		+2.61%	-8.73%

Feb. 10	Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
Jan. 08	Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding	CI

Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding

January 07, 2024

Vista Pharmaceuticals Limited announced a private placement of 2,66,667 pre-paid warrants at INR 2 per warrant for gross proceeds of INR 533,334 on January 8, 2024. The transaction will include participation from Pavan Sathvik Gilaka for 2.66.667 warrants. The company will issue shares on preferential basis.

The company will receive 25% of the total amount as upfront payment and the remaining 75% will be paid within 18 months as an exercise price. The transaction has been approved by board of directors of the company. The transaction is subject to shareholders approval to be obtained on January 8, 2024.

Latest news about Vista Pharmaceuticals Limited

Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 10	CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding	Jan. 07	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 10	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-12	CI
Vista Pharmaceuticals Limited Announces the Resignation of Mr. Nishant Talreja from the Post of Company Secretary, Compliance Officer and Key Managerial Personnel	23-06-16	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-30	CI
Vista Pharmaceuticals Limited Announces Change in Corporate Office Address	23-04-10	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Vista Pharmaceuticals Limited announced that it has received INR 61.895 million in funding	22-12-13	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-15	CI
Vista Pharmaceuticals Appoints Chairman	22-10-20	MT
Vista Pharmaceuticals Limited Announces Executive Changes	22-10-14	CI
Vista Pharmaceuticals Limited Approves Resignation of Narendra Gilaka as Independent Director of the Company	22-09-08	CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 66.895 million in funding	22-09-02	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-13	CI
Vista Pharmaceuticals Limited Announces Resignation of Akash Bhagadia as Company Secretary and Compliance Officer	22-06-27	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-30	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-30	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-13	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-14	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-30	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-12	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-11-12	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	20-09-14	CI

Chart Vista Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Vista Pharmaceuticals Limited is an India-based company that is engaged in manufacturing and selling of pharmaceutical, medical, and veterinary preparations. The Company also sells the products to its related companies, which are engaged in the manufacture of formulations. It offers over the counter and prescription generic drug products, consisting of tablets, capsules and liquids covering various therapeutic categories. Its products include tablet dosage forms in the United States market, such as Sulfamethoxazole & Trimethoprim, Acetaminophen, Bismuth Subsalicylate, Bismuth Subgallate, Ferrous Gluconate, Ferrous Sulfate, Pyrantel Pamoate and Isoxsuprine HCl and tablet dosage forms in the non-United States market, such as Aspirin, Atenolol, Mebendazole, Nefidipine, Quinine Sulfate, Ranitidine HCl, Magnesium Trisilicate Compound, Aluminium Hydroxide, Folic Acid and Captopril. Its capsule dosage forms in the non-United States market include Indomethacin, Piroxicam and Nefidipine.

Sector

Pharmaceuticals

Calendar

2024-08-11 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
VISTA PHARMACEUTICALS LIMITED	-8.73%	10.27M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+18.42%	42.25B
OTSUKA HOLDINGS CO., LTD.	+15.37%	21.27B
SANDOZ GROUP AG	+19.25%	15.23B
CIPLA LIMITED	+19.55%	14.36B
ZYDUS LIFESCIENCES LIMITED	+51.83%	12.74B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.40%	6.61B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	5.66B